Genentech Entered into an Exclusive WW License Agreement with Jemincare to Develop and Commercialize JMKX002992 for Prostate Cancer

Shots:

Jemincare to receive $60M up front & is also eligible to receive ~$590M in additional fees upon achievement of development, regulatory and sales-based milestones along with royalties on net sales. The collaboration focuses to develop new treatment options for patients with advanced prostate cancer
Jemincare to get an exclusive license to develop and commercialize JMKX002992 globally Genentech will be fully responsible for the development and commercialization costs
JMKX002992 is a novel oral degrader of the androgen receptor & is indicated to treat patients with prostate cancer who have developed resistance to current therapies

Ref: PRNewswire| Image: Genentech